SCHEMBL2810353

SCHEMBL2810353

CCCCCCCCCCN(CC(=O)O)CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.56
APP P05067 2/20 0.56
EYA2 O00167 1/20 0.56
ACE P12821 1/20 0.56
TSHR P16473 5/20 0.54
ALOX15 P16050 2/20 0.54
BLM P54132 2/20 0.54
PMP22 Q01453 2/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
CHRM2 P08172 1/20 0.54
ADRA2A P08913 1/20 0.54
DRD1 P21728 1/20 0.54
SLC6A2 P23975 1/20 0.54
SLC6A4 P31645 1/20 0.54
CYP2C19 P33261 1/20 0.54
ADRA1A P35348 1/20 0.54
DRD3 P35462 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HRH3 Q9Y5N1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924210 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL2810757 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL1316624 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL2947339 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL2442110 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL2804385 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL8662917 1.00 TDP1 (0.56) TDP1APPEYA2ACETSHR
SCHEMBL8054692 0.98 TDP1 (0.54) TDP1APPEYA2ACETSHR
SCHEMBL28318518 0.98 TDP1 (0.54) TDP1APPEYA2ACETSHR
SCHEMBL28286522 0.98 TDP1 (0.54) TDP1APPEYA2ACETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
US-5186940-A Antitumor agents THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1993-02-16 US disclosed
US-5178876-A Antitumor agents THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1993-01-12 US disclosed
US-5041581-A Antitumor agents THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS (US) 1991-08-20 US disclosed
EP-0248036-A1 HYDROPHOBIC CIS-PLATINUM COMPLEXES EFFICIENTLY INCORPORATED INTO LIPOSOMES. UNIV TEXAS (US) 1987-12-09 EP disclosed
WO-1987002364-A1 HYDROPHOBIC CIS-PLATINUM COMPLEXES EFFICIENTLY INCORPORATED INTO LIPOSOMES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1987-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 TDP1 3475/4885APP 3701/4885EYA2 1170/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB TDP1 2239/4885APP 3965/4885EYA2 2861/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA TDP1 3912/4885APP 2971/4885EYA2 3457/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA TDP1 2687/4885APP 3760/4885EYA2 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.